Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Esophageal Neoplasm Metastatic”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Early research (Phase 1)Study completedNCT00496860
What this trial is testing

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Who this might be right for
Progressive Metastatic Malignancies
Altor BioScience 26
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Large-scale testing (Phase 3)Looking for participantsNCT07487896
What this trial is testing

YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

Who this might be right for
Advanced Esophageal Squamous Cell Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd. 440
Testing effectiveness (Phase 2)Study completedNCT01612546
What this trial is testing

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

Who this might be right for
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the Stomach+11 more
City of Hope Medical Center 10
Testing effectiveness (Phase 2)Study completedNCT04068896
What this trial is testing

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Who this might be right for
Pancreatic CancerMetastatic Castration-resistant Prostate CancerBladder Cancer+8 more
NGM Biopharmaceuticals, Inc 89
Large-scale testing (Phase 3)Ended earlyNCT01450696
What this trial is testing

Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 296
Large-scale testing (Phase 3)Looking for participantsNCT05427383
What this trial is testing

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Who this might be right for
Stomach Cancer
Shanghai JMT-Bio Inc. 286
Early research (Phase 1)Study completedNCT01437007
What this trial is testing

TKM 080301 for Primary or Secondary Liver Cancer

Who this might be right for
Colorectal Cancer With Hepatic MetastasesPancreas Cancer With Hepatic MetastaseGastric Cancer With Hepatic Metastase+2 more
National Cancer Institute (NCI) 1
Early research (Phase 1)Study completedNCT03518554
What this trial is testing

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Who this might be right for
Non-small Cell Lung CancerHead and Neck CancerEsophageal Cancer+1 more
Jacobio Pharmaceuticals Co., Ltd. 38
Early research (Phase 1)Study completedNCT01598077
What this trial is testing

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Who this might be right for
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaHER2 + Breast CancerHER2 + Gastric Cancer+2 more
Novartis Pharmaceuticals 54
Not applicableUnknownNCT04825470
What this trial is testing

Liver Transplantation for Unresectable GIST Liver Metastases

Who this might be right for
Liver DiseasesLiver CancerLiver Metastases+25 more
Hospital Universitario Virgen de la Arrixaca 50
Testing effectiveness (Phase 2)Ended earlyNCT01832857
What this trial is testing

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Who this might be right for
Cancer
Cornerstone Pharmaceuticals 7
Early research (Phase 1)Study completedNCT00031681
What this trial is testing

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Who this might be right for
Advanced Adult Primary Liver CancerCarcinoma of the AppendixEstrogen Receptor-negative Breast Cancer+85 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Looking for participantsNCT06043466
What this trial is testing

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Who this might be right for
Colorectal CancerEsophagus CancerGastric Cancer+4 more
Chongqing Precision Biotech Co., Ltd 30
Not applicableStudy completedNCT01472419
What this trial is testing

Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Metastatic Esophageal Squamous Cell Carcinoma
Samsung Medical Center 239
Early research (Phase 1)Looking for participantsNCT06248411
What this trial is testing

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd. 189
Testing effectiveness (Phase 2)Study completedNCT00215995
What this trial is testing

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Who this might be right for
Esophageal CancerGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 21